Kymera Therapeutics (KYMR) Non-Current Deferred Tax Liability (2022 - 2023)
Kymera Therapeutics (KYMR) posted quarterly Non-Current Deferred Tax Liability of $68.3 million for Q4 2023, up 87.57% year-over-year from $36.4 million in Q4 2022, and up 87.57% quarter-over-quarter from $36.4 million in Q4 2022.
Powered by 
Analysis
Kymera Therapeutics (KYMR) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $68.3 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Non-Current Deferred Tax Liability rose 87.57% year-over-year to $68.3 million; the TTM figure through Dec 2023 stood at $68.3 million (up 87.57% YoY), while the FY2023 annual figure was $68.3 million, up 87.57% from the prior year.
- Non-Current Deferred Tax Liability improved to $68.3 million in Q4 2023 per KYMR's latest filing, from $36.4 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $68.3 million in Q4 2023 and bottomed at $36.4 million in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Kymera Therapeutics | 11.52 Bn | 10.83 Bn | - |